

Resource Summary Report

Generated by [dkNET](#) on Sep 8, 2026

NCI-H524

RRID:CVCL_1568

Type: Cell Line

Proper Citation

RRID:CVCL_1568

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1568

Proper Citation: RRID:CVCL_1568

Description: Cell line NCI-H524 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung small cell carcinoma

Defining Citation: [PMID:1320893](#), [PMID:1845952](#), [PMID:2388294](#), [PMID:2473086](#), [PMID:2985257](#), [PMID:2985258](#), [PMID:3335022](#), [PMID:6713399](#), [PMID:7720728](#), [PMID:8806092](#), [PMID:8806103](#), [PMID:11030152](#), [PMID:17426248](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27247353](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28766886](#), [PMID:30038707](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:32586373](#), [PMID:34439128](#), [PMID:35839778](#), [PMID:39154123](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H524

Synonyms: H524, H-524, NCIH524

Cross References: BTO:BTO_0004825, CLO:CLO_0008095, EFO:EFO_0002296, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5831, BioSample:SAMN03472976,

BioSample:SAMN10988203, cancercellines:CVCL_1568, CCRID:1101HUM-PUMC000356, Cell_Model_Passport:SIDM01129, ChEMBL-Cells:ChEMBL3308296, ChEMBL-Targets:ChEMBL2366342, CLS:305120, Cosmic:688024, Cosmic:844555, Cosmic:850442, Cosmic:877208, Cosmic:877358, Cosmic:908483, Cosmic:980933, Cosmic:1032399, Cosmic:1152472, Cosmic:1759289, Cosmic:1891904, Cosmic:2125200, Cosmic-CLP:908483, DepMap:ACH-000816, EGA:EGAS00001000978, GDSC:908483, GEO:GSM169442, GEO:GSM170710, GEO:GSM170712, GEO:GSM171880, GEO:GSM171881, GEO:GSM794292, GEO:GSM845548, GEO:GSM887435, GEO:GSM888515, GEO:GSM1670249, GEO:GSM1887893, GEO:GSM1887976, IARC_TP53:21575, IGRhCellID:NCIH524, KCB:KCB 2010137YJ, KCLB:90524, LiGeA:CCLE_825, LINCS_LDP:LCL-1857, PharmacODB:NCIH524_1119_2019, PRIDE:PXD011896, PRIDE:PXD030304, Progenetix:CVCL_1568, PubChem_Cell_line:CVCL_1568, Wikidata:Q54908075

ID: CVCL_1568

Record Creation Time: 20220427T220840+0000

Record Last Update: 20260905T181246+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H524.

Warning: Discontinued: KCLB; 90524

Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Balke-Want H, et al. (2026) c-JUN enhances CRISPR knockin anti-B7-H3 CAR T cell function in small cell lung cancer and thoracic SMARCA4-deficient undifferentiated tumors. Cell reports. Medicine, 7(1), 102549.

Schnabel JL, et al. (2025) IMPDH inhibition induces DNA replication stress and ATR sensitivity in Merkel cell carcinoma. iScience, 28(6), 112567.

Chatterjee D, et al. (2025) KSR1 Mediates Small Cell Lung Carcinoma Tumor Initiation and Cisplatin Resistance. Molecular cancer research : MCR, 23(6), 553.

Fnu T, et al. (2025) Sympathetic Neurons Promote Small Cell Lung Cancer through the α_2 -Adrenergic Receptor. *Cancer discovery*, 15(3), 616.

Ju Y, et al. (2025) Machine learning identified extrachromosomal DNA-related 12 gene signatures to predict cancer immunotherapy response. *Cancer cell international*, 25(1), 436.

De Rosa C, et al. (2025) DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer. *iScience*, 28(3), 111943.

Martin-Vega A, et al. (2024) ASCL1 Restrains ERK1/2 to Promote Survival of a Subset of Neuroendocrine Lung Cancers. *Molecular cancer therapeutics*, 23(12), 1789.

Wang Z, et al. (2024) Molecular subtypes of neuroendocrine carcinomas: A cross-tissue classification framework based on five transcriptional regulators. *Cancer cell*, 42(6), 1106.

Yin M, et al. (2024) A targeting nanoplatform for chemo-photothermal synergistic therapy of small-cell lung cancer. *International journal of cancer*, 155(11), 2094.

Yoon SJ, et al. (2023) Comprehensive Metabolic Tracing Reveals the Origin and Catabolism of Cysteine in Mammalian Tissues and Tumors. *Cancer research*, 83(9), 1426.

Martin-Vega A, et al. (2023) ASCL1-ERK1/2 Axis: ASCL1 restrains ERK1/2 via the dual specificity phosphatase DUSP6 to promote survival of a subset of neuroendocrine lung cancers. *bioRxiv : the preprint server for biology*.

Taniguchi H, et al. (2022) WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. *Cell reports*, 39(7), 110814.

Groves SM, et al. (2022) Archetype tasks link intratumoral heterogeneity to plasticity and cancer hallmarks in small cell lung cancer. *Cell systems*, 13(9), 690.

Takahashi N, et al. (2022) Replication stress defines distinct molecular subtypes across cancers. *Cancer research communications*, 2(6), 503.

Schenk MW, et al. (2021) Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer. *Nature communications*, 12(1), 6652.

Thomas A, et al. (2021) Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. *Cancer cell*, 39(4), 566.

Inoue Y, et al. (2021) Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer. *eLife*, 10.

Whalen KA, et al. (2019) Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer. *Molecular cancer therapeutics*, 18(11), 1926.